Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Endurance RP ( (HK:0575) ) is now available.
Endurance RP has reported a reduced loss of approximately US$2.22 million for the first half of 2025, primarily due to operating and R&D expenses. The company is making progress with its product Senstend™ in China, aiming for marketing approval by the end of 2025 and a commercial launch in early 2026. Additionally, Endurance RP is evaluating proposals for phase 3 clinical studies of Fortacin™ in the US and is in discussions for out-licensing opportunities. The company continues to supply Fortacin™ to European markets and is negotiating manufacturing terms in South-East Asia. Endurance RP is also advancing its Deep Longevity division, focusing on AI-driven aging clocks and expanding its business development strategies.
More about Endurance RP
Endurance RP is a company involved in the healthcare and life sciences sectors, focusing on the development and commercialization of pharmaceutical products and AI-driven technologies. Its primary products include Fortacin™ and Senstend™, with a market focus on China, the US, and Europe. The company is also expanding its Deep Longevity division, which specializes in AI-led deep learning technology for aging clocks.
Average Trading Volume: 62,048
Technical Sentiment Signal: Hold
Current Market Cap: HK$248M
Find detailed analytics on 0575 stock on TipRanks’ Stock Analysis page.